Human CellExp™ B7-2 /CD86, human recombinant

Biomolecule/Target: B7-2 /CD86

Synonyms: CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

Alternates names: CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

Taglines: Involved in innate immune responses by activating NF-κB-signaling pathway

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 942

NCBI Gene Symbol: CD86

Gene Source: Human

Accession #: P42081

Recombinant: Yes

Source: HEK293 cells

Purity by SDS-PAGE #: ≥95%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): Measured by its binding ability in a functional ELISA.

Biological activity: N/A

Results: N/A

Binding Capacity: Immobilized human CD28 at 5 μg/ml (100 μl/well) can bind human biotinylated CD86 with a linear range of 0.08 – 1.25 µg/ml.

Unit Definition: N/A

Molecular Weight: 26.8 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4.

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in distilled water.

Background Information: Cluster of Differentiation 86 (CD86) also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily. It is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 and CD80 together prime T cells. B7-2 was shown to promote the generation of mature APC (antigen presenting cells) repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB signaling pathway in macrophages. CD86 is thus regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to first-line therapy.

Amino acid sequence: N/A

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans